News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,146 Results
Type
Article (13863)
Company Profile (294)
Press Release (245989)
Section
Business (79319)
Career Advice (148)
Deals (13179)
Drug Delivery (32)
Drug Development (50282)
Employer Resources (31)
FDA (5669)
Job Trends (5111)
News (144052)
Policy (10013)
Tag
Academia (901)
Alliances (21465)
Alzheimer's disease (734)
Approvals (5643)
Artificial intelligence (62)
Bankruptcy (97)
Best Places to Work (4496)
Biotechnology (242)
Breast cancer (64)
Cancer (684)
Cardiovascular disease (62)
Career advice (129)
CAR-T (55)
Cell therapy (174)
Clinical research (39781)
Collaboration (233)
Compensation (95)
COVID-19 (1002)
C-suite (66)
Cystic fibrosis (66)
Data (779)
Diabetes (73)
Diagnostics (1199)
Earnings (28971)
Events (46817)
Executive appointments (185)
FDA (5954)
Funding (239)
Gene editing (55)
Gene therapy (145)
GLP-1 (299)
Government (1063)
Healthcare (6531)
Infectious disease (1036)
Inflammatory bowel disease (94)
IPO (7175)
Job creations (859)
Job search strategy (125)
Layoffs (184)
Legal (1373)
Lung cancer (110)
Manufacturing (74)
Medical device (2552)
Medtech (2553)
Mergers & acquisitions (6099)
Metabolic disorders (222)
Neuroscience (937)
NextGen Class of 2024 (1998)
Non-profit (843)
Northern California (938)
Obesity (122)
Opinion (91)
Parkinson's disease (60)
Patents (51)
People (24959)
Pharmaceutical (49)
Phase I (13990)
Phase II (18503)
Phase III (11730)
Pipeline (318)
Postmarket research (846)
Preclinical (5918)
Radiopharmaceuticals (204)
Rare diseases (166)
Real estate (1409)
Regulatory (8200)
Research institute (930)
Southern California (857)
Startups (1963)
United States (7520)
Vaccines (159)
Weight loss (76)
Date
Today (118)
Last 7 days (598)
Last 30 days (2276)
Last 365 days (20678)
2024 (18875)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16821)
Australia (2835)
California (2123)
Canada (704)
China (159)
Colorado (79)
Connecticut (84)
Europe (36224)
Florida (221)
Georgia (62)
Illinois (125)
Indiana (54)
Kansas (55)
Maryland (298)
Massachusetts (1685)
Michigan (48)
Minnesota (93)
New Jersey (537)
New York (603)
North Carolina (397)
Northern California (938)
Ohio (78)
Pennsylvania (424)
South America (207)
Southern California (857)
Texas (220)
Washington State (215)
260,146 Results for "zevra therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Adcomms
FDA Questions Strength of Evidence Backing Zevra’s Rare Disease Therapy Ahead of Adcomm
The Genetic Metabolic Diseases Advisory Committee will meet on Friday to discuss Zevra’s modified scale to describe the efficacy of its drug candidate for the treatment of Niemann-Pick disease type C.
August 1, 2024
·
2 min read
·
Tristan Manalac
Business
Zevra Therapeutics Expands Executive Leadership Team
Zevra Therapeutics, Inc. today announced the appointments of Rahsaan W. Thompson as Chief Legal Officer, Secretary and Compliance Officer, and Alison Peters as Chief People Officer.
June 25, 2024
·
7 min read
BioMidwest
Zevra Therapeutics to Participate at Upcoming May 2024 Investor Events
Zevra Therapeutics, Inc., a rare disease therapeutics company, announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at several upcoming investor events in May 2024.
May 9, 2024
·
3 min read
Adcomms
Zevra Gains Support of Adcomm, Clears Hurdle for Potential Rare Disease Approval
An FDA advisory committee agreed on Friday that Zevra Therapeutics had provided sufficient efficacy data supporting the approval of arimoclomol for Niemann-Pick disease type C.
August 5, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates
November 12, 2024
·
18 min read
Press Releases
Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13
November 6, 2024
·
2 min read
BioMidwest
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
Orsini Specialty Pharmacy, and Zevra Therapeutics, Inc. announced that Orsini is now the pharmacy partner for OLPRUVA® for oral suspension.
June 18, 2024
·
7 min read
Business
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
Zevra Therapeutics, Inc., a rare disease therapeutics company, provided corporate updates and reported its financial results for the first quarter ended March 31, 2024.
May 8, 2024
·
17 min read
Zevra Therapeutics to Participate at Upcoming Investor Conferences
Zevra Therapeutics, Inc. today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at upcoming investor conferences in March 2024.
February 28, 2024
·
3 min read
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
Zevra Therapeutics, Inc. today announced that Neil F. McFarlane, Zevra’s President and Chief Executive Officer, has issued a Letter to Stockholders providing a review of key accomplishments and outlook for 2024.
April 29, 2024
·
16 min read
1 of 26,015
Next
